All In Biotech

Drug Trial Radar · NCT05141721

A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

A Phase 2/3, Randomized, Open-Label Study of Maintenance GRT-C901/GRT-R902, A Neoantigen Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer

Last checked: Nov 20, 2026Latest source record: May 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 700 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

700

Planned (sponsor's estimate)

Start

Feb 12, 2022

Primary completion

Mar 2027

Study completion Mar 2027

Sponsor

Lead sponsor
Seattle Project CorporationIndustry
Sponsor type
Industry
First posted
Dec 2, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the Phase 2 portion of the study is to characterize the clinical activity of maintenance therapy with GRT-C901/GRT-R902 (patient-specific vaccines) in combination with checkpoint inhibitors in addition to fluoropyrimidine/bevacizumab versus a fluoropyrimidine/bevacizumab alone as assessed by molecular response which is based on changes in circulating tumor (ct)DNA. The primary objective of the Phase 3 portion is to demonstrate clinical efficacy of the regimen as assessed by progression-free survival.

Conditions

  • Colorectal Neoplasms

Interventions

  • GRT-C901Drug

    A patient-specific neoantigen cancer vaccine administered via intramuscular (IM) injection as prime and single boost at a dose of 1x10\^12 viral particles 2 times over the course of the first year.

  • GRT-R902Drug

    A patient-specific neoantigen cancer vaccine boost, administered via IM injection at a dose of 30ug 4 times over the course of the first year.

  • AtezolizumabDrug

    Atezolizumab will be administered via intravenous (IV) infusion at a dose of 1680 mg once every 4 weeks.

  • IpilimumabDrug

    Ipilimumab will be administered via subcutaneous (SC) injection at a dose of 30 mg with the first dose of GRT-C901 and GRT-R902.

  • Fluoropyrimidine plus leucovorinDrug

    Fluoropyrimidine (infusional 5-FU or capecitabine) and leucovorin administered as maintenance therapy per standard of care.

  • BevacizumabDrug

    Bevacizumab administered as maintenance therapy per standard of care.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 2: Molecular response defined as ≥ 30% decrease from baseline in circulating tumor DNA (ctDNA)Time frame: Baseline and up to 27 months
  2. Phase 3: Progression-free survival per Immune-based Response Evaluation Criteria in Solid Tumors (iRECIST) as assessed by blinded independent review committee (IRC)Time frame: Up to 60 months

Locations

43 sites in 1 country. Site status is shown where the registry gives one.

  • Banner MD Anderson

    Gilbert, Arizona

  • Highlands Oncology

    Springdale, Arkansas

  • U.S.C Norris Cancer Center, Keck School of Medicine, Division of Medical Oncology

    Los Angeles, California

  • University of California - Irvine (UCI)

    Orange, California

  • University of California Los Angeles (UCLA)

    Santa Monica, California

  • Rocky Mountain Cancer Centers - USOR

    Denver, Colorado

  • Eastern CT Hematology and Oncology Associates (ECHO)

    Norwich, Connecticut

  • Lynn Cancer Institute - Boca Raton Regional Hospital

    Boca Raton, Florida

  • University of Miami

    Miami, Florida

  • Miami Cancer Institute at Baptist Health South Florida (USOR site)

    Miami, Florida

  • Mount Sinai Comprehensive Cancer Center

    Miami Beach, Florida

  • Orlando Health

    Orlando, Florida

  • Advanced Research (Oncology & Hemotology Associates of West Broward)

    Tamarac, Florida

  • University of Illinois at Chicago

    Chicago, Illinois

  • University of Chicago

    Chicago, Illinois

  • Indiana University

    Indianapolis, Indiana

  • University of Kansas Medical Center

    Fairway, Kansas

  • Norton Cancer Institute

    Louisville, Kentucky

  • American Oncology Partners of Maryland, PA

    Bethesda, Maryland

  • Barbara Ann Karmanos Cancer Institute

    Detroit, Michigan

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

  • Astera Cancer Care

    East Brunswick, New Jersey

  • Summit Health

    Florham Park, New Jersey

  • Morristown Medical Center

    Morristown, New Jersey

  • Rutgers

    New Brunswick, New Jersey

  • NYU Langone Health

    New York, New York

  • Columbia University Irving Medical Center

    New York, New York

  • New York Cancer and Blood

    Port Jefferson Station, New York

  • Christ Hospital Cancer Center

    Cincinnati, Ohio

  • Northwest Cancer Specialists DBA Compass Oncology - USOR

    Portland, Oregon

  • Sidney Kimmel Medical College at Thomas Jefferson University

    Philadelphia, Pennsylvania

  • Allegheny General Hospital

    Pittsburgh, Pennsylvania

  • Prisma Health

    Greenville, South Carolina

  • Tennessee Oncology - Sarah Cannon Research Institute

    Nashville, Tennessee

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Texas Oncology PA - USOR

    Austin, Texas

  • Texas Oncology - Dallas Sammons

    Dallas, Texas

  • MD Anderson

    Houston, Texas

  • Baylor Scott and White

    Temple, Texas

  • Huntsman Cancer Institute at University of Utah

    Salt Lake City, Utah

Showing 40 of 43 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.